

Serum \hat{I}^2 -microglobulin and prediction of progression

Lancet, The

339, 1436-1440

DOI: [10.1016/0140-6736\(92\)92030-j](https://doi.org/10.1016/0140-6736(92)92030-j)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Markers as time-dependent covariates in relative risk regression. <i>Statistics in Medicine</i> , 1993, 12, 2087-2098.	1.6	10
2	Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. <i>Lancet, The</i> , 1993, 342, 268-272.	13.7	436
3	Racial Differences in Serum $\hat{A}2$ -Microglobulin in Persons with Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 1993, 167, 1259-1259.	4.0	2
4	Preventive Health Care for Adults With HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 1993, 269, 1144.	7.4	39
5	Predicting the Outcomes of Human Immunodeficiency Virus Infection. <i>Archives of Internal Medicine</i> , 1993, 153, 2749.	3.8	14
6	Hepatitis C Virus Infection and Progression of Infection Due to Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1993, 16, 182-182.	5.8	27
7	HIV-1 Antibodies and Serology. <i>Clinics in Laboratory Medicine</i> , 1994, 14, 257-269.	1.4	4
8	Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group. <i>Blood</i> , 1994, 83, 1958-1962.	1.4	30
9	Soluble Receptors for Tumor Necrosis Factor as Predictors of Progression to AIDS in Asymptomatic Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 1994, 169, 739-745.	4.0	109
10	Management of Antiretroviral Drug Therapy in Human Immunodeficiency Virus Infection. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 1994, 31, 169-196.	6.1	5
11	Serum concentrations of soluble intercellular adhesion molecule-1 and progress towards disease in patients infected with HIV. <i>Journal of Infection</i> , 1994, 29, 271-282.	3.3	21
12	Psychosocial correlates and the effects of behavioral interventions on the course of human immunodeficiency virus infection in homosexual men. <i>Patient Education and Counseling</i> , 1994, 24, 237-247.	2.2	8
13	Beta-2 microglobulin as a predictor of prognosis in HIV-infected men with haemophilia: a proposed strategy for use in clinical care. <i>British Journal of Haematology</i> , 1994, 86, 366-371.	2.5	18
14	HIV: The surgeon's perspective Part 1. Update of pathogenesis, epidemiology and management and risk of nosocomial transmission. <i>British Journal of Oral and Maxillofacial Surgery</i> , 1994, 32, 222-230.	0.8	5
15	The Chemical Pathology of AIDS. <i>Annals of Clinical Biochemistry</i> , 1994, 31, 401-409.	1.6	2
16	Clinical Features and Serum $\hat{I}22$ -Microglobulin Levels in HIV-1 Positive and Negative Tanzanian Patients with Tuberculosis. <i>International Journal of STD and AIDS</i> , 1995, 6, 278-283.	1.1	5
17	Prognostic value of adenosine deaminase compared to other markers for progression to acquired immunodeficiency syndrome among intravenous drug users. <i>Journal of Medical Virology</i> , 1995, 45, 203-210.	5.0	8
18	Levels of the circulating cell adhesion molecule E-selectin and disease progression in HIV infection. <i>Infection</i> , 1995, 23, 207-211.	4.7	14

#	ARTICLE	IF	CITATIONS
19	HIV-1 Messenger RNA in Peripheral Blood Mononuclear Cells as an Early Marker of Risk for Progression to AIDS. <i>Annals of Internal Medicine</i> , 1995, 123, 641.	3.9	77
20	Pharmacokinetic Optimisation of Antiretroviral Therapy in Patients with HIV Infection. <i>Clinical Pharmacokinetics</i> , 1995, 29, 46-65.	3.5	14
21	Prognostic Value of Combined Response Markers Among Human Immunodeficiency Virus-Infected Persons: Possible Aid in the Decision to Change Zidovudine Monotherapy. <i>Clinical Infectious Diseases</i> , 1995, 20, 352-362.	5.8	19
22	Early Intervention for Persons Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1995, 20, S3-S22.	5.8	7
23	Sustained Increases In Cd4 Cell Counts In Asymptomatic Human. <i>Journal of Infectious Diseases</i> , 1995, 171, 523-530.	4.0	115
24	Statistical Issues in the Evaluation of Markers of HIV Progression. <i>International Statistical Review</i> , 1995, 63, 179.	1.9	4
25	In Vitro T Cell Function, Delayed-Type Hypersensitivity Skin Testing, and CD4+ T Cell Subset Phenotyping Independently Predict Survival Time in Patients Infected with Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 1995, 172, 79-87.	4.0	145
26	Massage Therapy is Associated with Enhancement of the Immune System's Cytotoxic Capacity. <i>International Journal of Neuroscience</i> , 1996, 84, 205-217.	1.6	216
27	Immunological and virological markers of HIV-disease progression. <i>Journal of the Association of Nurses in AIDS Care</i> , 1996, 7, 15-27.	1.0	17
28	An Approach to the Validation of Markers for Use in AIDS Clinical Trials. <i>Clinical Infectious Diseases</i> , 1997, 24, 764-774.	5.8	73
29	Clinical Markers of the Presence of Dementia and Neuropsychological Impairment in HIV Infection. <i>Journal of Neuro-AIDS</i> , 1997, 1, 31-48.	0.2	5
30	BETA-2-MICROGLOBULIN LEVELS IN HUMAN-IMMUNODEFICIENCY VIRUS INFECTED SUBJECTS. <i>Medical Journal Armed Forces India</i> , 1997, 53, 251-254.	0.8	0
31	Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment. <i>BioDrugs</i> , 1997, 8, 243-249.	4.6	0
32	Circulating cell adhesion molecules in HIV1-infected patients as indicator markers for AIDS progression. <i>Research in Immunology</i> , 1997, 148, 109-117.	0.9	36
34	A flow cytometric immunoassay for β_2 -microglobulin in whole blood. <i>Journal of Immunological Methods</i> , 1997, 210, 79-87.	1.4	14
35	Effect of cessation of drug misuse on the immune status of HIV-infected injecting drug users. <i>Addiction Biology</i> , 1997, 2, 95-99.	2.6	1
36	Clinical Progression of HIV Infection: Role of NK Cells. <i>Scandinavian Journal of Immunology</i> , 1997, 46, 91-95.	2.7	64
37	Serum levels of β_2 -microglobulin, neopterin, TNF- α and soluble receptors of TNF- α and interleukin-2 in intravenous drug abusers according to HIV-1 status and stage of the HIV-1 infection. <i>Clinical Microbiology and Infection</i> , 1998, 4, 4-10.	6.0	10

#	ARTICLE	IF	CITATIONS
38	Protein levels of interleukin-12 p70 Holomer, its p40 chain and interferon-gamma during advancing HIV infection. <i>Journal of Infection</i> , 1998, 37, 282-286.	3.3	10
39	Tumor Necrosis Factor \hat{I}^2 and Soluble APO-1/Fas Independently Predict Progression to AIDS in HIV-Seropositive Patients. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 835-843.	1.1	18
40	Effect of Human Immunodeficiency Virus Infection on Serum Beta2-Microglobulin Levels in Pregnant Women. <i>Obstetrics and Gynecology</i> , 1999, 94, 537-542.	2.4	0
41	Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. <i>Haemophilia</i> , 1999, 5, 9-16.	2.1	69
42	HIV and the Returning Expatriate. <i>Journal of Travel Medicine</i> , 1999, 6, 99-106.	3.0	7
43	Effect of human immunodeficiency virus infection on serum beta2-microglobulin levels in pregnant women. <i>Obstetrics and Gynecology</i> , 1999, 94, 537-542.	2.4	3
44	Soluble tumor necrosis factor alpha receptors (sTNF-Rs) in HIV-1-infected intravenous drug users: change in circulating sTNF-R type II level and survival for AIDS patients. <i>European Journal of Epidemiology</i> , 2000, 16, 209-216.	5.7	4
45	HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. <i>Blood</i> , 2000, 96, 250-258.	1.4	68
46	Immune disorders. , 2000, , 201-217.		0
47	Prognostic Value of Plasma Markers of Immune Activation in Patients with Advanced HIV Disease Treated by Combination Antiretroviral Therapy. <i>Clinical Immunology</i> , 2001, 99, 347-352.	3.2	26
48	Determination of \hat{I}^2 -2 Microglobulin Levels in Plasma Using a High-Throughput Mass Spectrometric Immunoassay System. <i>Analytical Chemistry</i> , 2001, 73, 3294-3299.	6.5	86
49	Detection and Quantification of \hat{I}^2 -2-Microglobulin Using Mass Spectrometric Immunoassay. <i>Analytical Biochemistry</i> , 2001, 289, 26-35.	2.4	73
50	Contribution of Peaks of Virus Load to Simian Immunodeficiency Virus Pathogenesis. <i>Journal of Virology</i> , 2002, 76, 2573-2578.	3.4	12
51	\hat{I}^2 microglobulin serum levels and prediction of survival in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2002, 9, 242-246.	3.0	9
52	\hat{I}^2 -microglobulin as a negative growth regulator of myeloma cells. <i>British Journal of Haematology</i> , 2002, 118, 495-505.	2.5	27
53	Influence of Hepatitis C Virus Coinfection on Failure of HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy to Achieve Normal Serum \hat{I}^2 Microglobulin Levels. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003, 22, 194-196.	2.9	7
54	\hat{I}^2 -microglobulin as a potential initiator of inflammatory responses. <i>Trends in Immunology</i> , 2003, 24, 228-229.	6.8	44
55	Comparative Urine Protein Phenotyping Using Mass Spectrometric Immunoassay. <i>Journal of Proteome Research</i> , 2003, 2, 191-197.	3.7	65

#	ARTICLE	IF	CITATIONS
56	Î2-Microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. <i>Blood</i> , 2003, 101, 4005-4012.	1.4	87
58	Correlation of serum B lymphocyte stimulator and Î2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1050-1055.	0.9	68
59	In Vivo Effects of HIV-1 Exposure in the Presence and Absence of Single-Dose Nevirapine on Cellular Plasma Activation Markers of Infants Born to HIV-1-Seropositive Mothers. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 545-553.	2.1	25
60	Immune Function and Phenotype Before and After Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 2006, 21, 376.	0.3	19
61	Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: Correlation with clinical outcome. <i>Human Immunology</i> , 2007, 68, 894-900.	2.4	8
63	Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: Comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution. <i>Clinical Immunology</i> , 2009, 133, 238-244.	3.2	34
64	Structural modeling and biochemical studies reveal insights into the molecular basis of the recognition of Î2 microglobulin by antibody BBM.1. <i>Journal of Molecular Recognition</i> , 2009, 22, 465-473.	2.1	3
65	Estimation of virological and immunological parameters in subjects from South India infected with human immunodeficiency virus type 1 clade C and correlation of findings with occurrence of neurological disease. <i>Journal of NeuroVirology</i> , 2009, 15, 25-35.	2.1	12
66	Use of predictive markers of HIV disease progression in vaccine trials. <i>Vaccine</i> , 2009, 27, 1997-2015.	3.8	18
69	Urinary Î2-microglobulin as an alternative marker for fetal inflammatory response and development of bronchopulmonary dysplasia in premature infants. <i>Journal of Perinatology</i> , 2011, 31, 330-334.	2.0	15
70	Elevated Concentrations of Milk Î2-Microglobulin Are Associated with Increased Risk of Breastfeeding Transmission of HIV-1 (Vertical Transmission Study). <i>Journal of Proteome Research</i> , 2013, 12, 5616-5625.	3.7	8
71	Label-free proteomic analysis of PBMCs reveals gender differences in response to long-term antiretroviral therapy of HIV. <i>Journal of Proteomics</i> , 2015, 126, 46-53.	2.4	9
72	Î2-Microglobulin and TIMP1 Are Linked Together in Cardiorenal Remodeling and Failure. <i>CardioRenal Medicine</i> , 2015, 5, 1-11.	1.9	16
73	Oxidant Mechanisms in Renal Injury and Disease. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 119-146.	5.4	468
74	Urinary Î2 microglobulin and bronchopulmonary dysplasia: Trends in preterm infants. <i>Pediatrics International</i> , 2017, 59, 1169-1173.	0.5	4
75	Long-Term Follow-up of HIV Positive Asymptomatic Patients Having Received Cyclosporin A. <i>Advances in Experimental Medicine and Biology</i> , 1995, 374, 229-234.	1.6	35
76	Serum Î2-Microglobulin at HIV-1 Seroconversion As a Predictor of Severe Immunodeficiency During 10 Years of Followup. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 13, 262-266.	0.3	9
77	Correlation Between Plasma HIV-1 RNA Levels and the Rate of Immunologic Decline. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 14, 408-414.	0.3	18

#	ARTICLE	IF	CITATIONS
78	Pathogenesis of human immunodeficiency virus infection. Microbiological Reviews, 1993, 57, 183-289.	10.1	893
79	HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood, 2000, 96, 250-258.	1.4	15
80	The chronology of HIV-induced disease. Medical Journal of Australia, 1993, 158, 3-5.	1.7	6
81	Prognostic Markers and Immunological Reconstitution During HIV-1 Infection. , 2000, , 243-259.		0
82	LABORATORY MARKERS ASSOCIATED WITH PROGRESSION OF HIV INFECTION. Indian Journal of Medical Microbiology, 2004, 22, 7-15.	0.8	7
83	24. It is HIV: immediate and long-term plans. Medical Journal of Australia, 1993, 158, 323-325.	1.7	3
86	Mechanisms of Host Resistance Against HIV Infection and Progression to AIDS. Sultan Qaboos University Medical Journal, 2007, 7, 82-96.	1.0	7
87	Epigenetic clock analysis in methamphetamine dependence. Psychiatry Research, 2022, 317, 114901.	3.3	3
88	The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients. Annals of Hematology, 0, , .	1.8	0